Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population

The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Type 2 Diabetes Mellitus (T2DM) Biological Age Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Metabolic Dysfunction-Associated Steatotic Liver Disease Nutritional and Metabolic Diseases

Age range

20 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000

Ningbo, Zhejiang, 315000, China

Location status: Recruiting

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Abdominal ultrasound data available in annual health check-up records
At least one of the following five metabolic indicators recorded annually:

(1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c)

Exclusion criteria

Age <20 or >90 years
Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection)
Type 2 diabetes mellitus at baseline
Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)

Treatment and study plan

Observational

Other

Observational

Primary outcomes

Incidence of onset T2DM

Time frame: through study completion, an average of 3 year

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

Ningbo No. 1 Hospital

Other

Registry information

Official study title

Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population: a Cohort Study

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: May 22, 2025
Registry last updated: Jun 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting